| (Values in U.S. Thousands) | Dec, 2014 | Dec, 2013 | Dec, 2012 | Mar, 2026 | Mar, 2026 |
| Sales | 15,280 | 13,050 | 12,350 | 0 | 0 |
| Sales Growth | +17.09% | +5.67% | unch | unch | unch |
| Net Income | -5,080 | -6,380 | -3,350 | 0 | 0 |
| Net Income Growth | +20.38% | -90.45% | unch | unch | unch |
Tribute Pharmaceuticals Canada Inc (TBUFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Tribute Pharmaceuticals Canada Inc. is a specialty pharmaceutical company engaged in the acquisition, licensing and management of prescription pharmaceuticals products primarily in Canada. Its products portfolio includes Cambia (R), Bezalip (R) SR, Soriatane (R), NeoVisc (R), Uracyst (R) and Collatamp G (R). The company focuses on various therapeutic areas, such as pain, urology, dermatology, and endocrinology/cardiology. Tribute Pharmaceuticals Canada Inc. is headquartered in Milton, Canada.
Fiscal Year End Date: 12/31